No Data
Form 144 | Black Diamond Therapeutics(BDTX.US) Insider Proposes to Sell 360K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 9, $Black Diamond Therapeutics(BDTX.US)$ Insider David Esptein intends to sell 75,000 shares of its common stock on Jul 9, with a total market value of approximately $360K.
Black Diamond Theraptcs Is Maintained at Overweight by Piper Sandler
Black Diamond Theraptcs Is Maintained at Overweight by Piper Sandler
Black Diamond Theraptcs Price Target Maintained With a $12.00/Share by Piper Sandler
Black Diamond Theraptcs Price Target Maintained With a $12.00/Share by Piper Sandler
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $12
Piper Sandler analyst Joseph Catanzaro maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success ra
Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now?